Company profile for Poxel

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Poxel, we are a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time. We believe that targeting cellular energy regulation pathways for the treatment of metabolic diseases, including typ...
At Poxel, we are a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time. We believe that targeting cellular energy regulation pathways for the treatment of metabolic diseases, including type 2 diabetes is of critical importance as disbalances are at the root of those diseases. All three of our clinical stage pipeline programs address significant targets in the energy metabolism pathways.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
France
Address
Address
Immeuble Le Sunway 259-261 Avenue Jean Jaurès 69007 Lyon
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-12-10/poxel-publishes-its-financial-results-for-the-first-half-of-2025

PHARMIWEB
10 Dec 2025

https://www.businesswire.com/news/home/20251123464616/en/POXEL-SA-Update-on-the-Proposed-Recovery-Plan-and-Organisation-of-a-Webinar

BUSINESSWIRE
24 Nov 2025

https://www.businesswire.com/news/home/20251113331668/en/Poxel-Reports-Revenue-for-the-Third-Quarter-2025

BUSINESSWIRE
13 Nov 2025

https://www.businesswire.com/news/home/20251031569100/en/Appointment-of-Yves-Decadt-as-Member-of-Poxels-Board-of-Directors

BUSINESSWIRE
31 Oct 2025

https://www.pharmiweb.com/press-release/2025-10-16/poxel-reports-financial-results-for-full-year-2024-and-provides-operational-and-financial-update-1

PHARMIWEB
16 Oct 2025

https://www.businesswire.com/news/home/20250731189710/en/Following-the-Filing-for-the-Opening-of-Reorganization-Proceedings-Poxel-Announces-Changes-to-Its-Corporate-Governance

BUSINESSWIRE
01 Aug 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty